F
Filip K. Knop
Researcher at University of Copenhagen
Publications - 523
Citations - 17834
Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.
Papers
More filters
Journal ArticleDOI
Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide
TL;DR: Data was used from Danish population-based medical databases to examine whether routine clinical care liraglutide initiators would have been eligible for participation in phase III RCTs called the LiragLutide Effect and Action in Diabetes (LEAD) 1–5 trials.
Journal ArticleDOI
Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Andrea Tura,Jonatan I. Bagger,Eleuterio Ferrannini,Jens J. Holst,Filip K. Knop,Tina Vilsbøll,Andrea Mari +6 more
TL;DR: Estimating incretin sensitivity of the beta cell during oral glucose tolerance tests found relative incretIn insensitivity is partly compensated for by higher incRetin secretory responses.
Journal ArticleDOI
Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes
TL;DR: Co-formulations such as IDegLira are likely to be increasingly preferred over stepwise addition and titration of the individual agents in the management of T2D.
Journal ArticleDOI
Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation.
Simon Veedfald,Astrid Plamboeck,Bolette Hartmann,Lars Bo Svendsen,Tina Vilsbøll,Filip K. Knop,Jens J. Holst +6 more
TL;DR: In controls, but not in the vagotomized participants, intravenous glucose significantly inhibited PP secretion suggesting a vagal glucose sensing mechanism dependent on intact vagal innervation.
Journal ArticleDOI
Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH2 on GIP actions in humans.
Lærke S. Gasbjerg,Emilie Johanning Bari,Signe Stensen,Bjørn Hoe,Amalie R. Lanng,David S. Mathiesen,Mikkel B. Christensen,Bolette Hartmann,Jens J. Holst,Mette M. Rosenkilde,Filip K. Knop +10 more
TL;DR: GIP(3‐30)NH2 provides extensive, dose‐dependent inhibition of the GIP receptor in humans, with most pronounced effects of the doses 200 to 2000 pmol/kg/min within the tested range.